top of page
Search
Is this A for Gift Shareholders of Echo IQ Limited - EchoSolv HF Validated at Mayo Clinic Platform – Lining Up for FDA 510(k) Submission
Echo IQ Limited (ASX: EIQ) is pushing its cardiology decision-support platform into the heart failure space, with its EchoSolv HF algorithm now validated through the Mayo Clinic Platform’s independent “Validate” program in the United States. The Company, based in Sydney with operations anchored out of Western Australia, has completed what it describes as the final clinical requirement ahead of a planned FDA 510(k) submission for EchoSolv HF – a heart failure decision-support
Noel Ong
4 days ago7 min read
bottom of page